Steatohepatitis/Metabolic Liver Disease News

Amsety and the Fatty Liver Foundation announced the launch of the “Kiss and Click” campaign designed to raise awareness about fatty liver disease and liver health, according to a press release.

Results from an online survey conducted by the Canadian Liver Foundation revealed that 56% of Canadians were unaware that nonalcoholic fatty liver disease can lead to liver cancer, the need for liver transplantation or death, and 89% had little to no knowledge of NAFLD, according to a press release.

Alnylam Pharmaceuticals announced that givosiran, an investigational RNAi therapeutic in development for the treatment of acute hepatic porphyria, met its ENVISION phase 3 primary efficacy endpoint of reduction in the annualized rate of composite porphyria attacks compared with placebo, according to a press release and conference call.

Comprehensive continuous care intervention with a ketogenic diet significantly improved surrogate markers of nonalcoholic fatty liver disease and advanced fibrosis in patients with type 2 diabetes after 1 year, according to data published in BMJ Open.

NGM282 improved the histological features of nonalcoholic steatohepatitis in 12 weeks with significant reductions in nonalcoholic fatty liver disease activity score as well as noninvasive imaging and serum markers, according to a study published in Hepatology.

Echosens announced the release of a white paper on nonalcoholic fatty liver disease that provides details on risk factors affecting U.S. patients along with solutions for early detection to improve awareness of the increasingly prevalent disease, according to a press release.

The beginning of 2019 has already seen several significant advancements for the field of nonalcoholic steatohepatitis, from the inaugural NASH-TAG meeting to the recently announced positive results from the phase 3 study of Ocaliva.

Intercept Pharmaceuticals announced that Ocaliva met its phase 3 study primary endpoint of fibrosis improvement by 1 stage or more with no worsening of nonalcoholic steatohepatitis, according to a press release and investor call.

The second annual International NASH Day — a public education campaign for nonalcoholic steatohepatitis — will be led this year by the Global Liver Institute and take place on June 12, according to a press release.

3-V Biosciences has entered an exclusive license agreement with Ascletis Pharma for Ascletis to develop, manufacture and commercialize 3-V Biosciences’ nonalcoholic steatohepatitis therapy TVB-2640 in Greater China, according to a press release.